-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lilly, Vir Biotech, and GlaxoSmithKline (GSK) recently announced the top-line data of the expanded Phase 2 BLAZE-4 trial, which studied patients with mild to moderate COVID-19 Low-risk adult patients.
In addition, in terms of the key virological secondary endpoint of the new coronavirus (SARS-CoV-2) viral load from baseline inspection to the average change on days 3, 5, and 7, compared with placebo, the combination of bamlanivimab and VIR-7831 The use of the drug resulted in a statistically significant reduction in viral load.
Bamlanivimab and VIR-7831 are two monoclonal antibodies that bind to different regions of the SARS-CoV-2 spike protein.
Based on the above data, the three companies plan to negotiate with global regulatory agencies including the US FDA on the possibility of combining bamlanivimab and VIR-7831 to treat COVI-19.
VIR-7831 is a new type of coronavirus (SARS-CoV-2) monoclonal antibody with dual functions.
Just recently, GlaxoSmithKline and Vir submitted an application to the U.
The FDA EUA submission is based on an interim analysis of the efficacy and safety data of the COMET-ICE (COVID-19 Monoclonal Antibody Efficacy Trial-Early Care Intention) Phase 3 trial.
bamlanivimab (LY-CoV555) is a potent, neutralizing IgG1 monoclonal antibody against SARS-CoV-2 spike protein.
In February of this year, the US FDA granted emergency use authorization (EUA) for the neutralizing antibody etesevimab 1400mg and bamlanivimab 700mg double antibody therapy.
etesevimab (JS016 or LY-CoV016) is a recombinant fully human monoclonal neutralizing antibody jointly developed by Junshi Biotechnology and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS), which specifically binds to SARS-CoV-2 surface spikes with high affinity Protein receptor binding domain, and can effectively block the combination of the virus and the host cell surface receptor ACE2.
Note: The original text has been deleted
Original source: Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
